Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203654 | 0.83 | AKR1B1 (0.50) | AKR1B1HSPA5TSHRHIF1ACYP2D6 | |
| SCHEMBL8569167 | 0.82 | GABRA1 (0.41) | TSHRCYP2D6ATM | |
| SCHEMBL3068210 | 0.81 | HSPA5 (0.48) | AKR1B1HSPA5TSHRHIF1ACYP2D6 | |
| SCHEMBL3860837 | 0.81 | AKR1B1 (0.57) | AKR1B1HSPA5TSHRHIF1ACYP2D6 | |
| SCHEMBL28209919 | 0.81 | AKR1B1 (0.57) | AKR1B1HSPA5TSHRHIF1ACYP2D6 | |
| SCHEMBL5298485 | 0.80 | NPC1 (0.54) | — | |
| SCHEMBL22275806 | 0.80 | GLS (0.47) | CYP2D6ATM | |
| SCHEMBL5738109 | 0.80 | AKR1B1 (0.61) | AKR1B1HSPA5TSHRHIF1ACYP2D6 | |
| SCHEMBL22316652 | 0.78 | KMT2A (0.45) | TSHRMAPTKDM4ESIGMAR1ATM | |
| SCHEMBL20918037 | 0.78 | CYP1A2 (0.39) | TSHRCYP2D6MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4249480-A1 | DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Northwest A&F University (CN) | 2023-09-27 | — | — | EP | disclosed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-08-15 | — | — | US | disclosed |
| CN-1906200-A | Novel compounds | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1687311-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049620-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
| EP-0923539-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2002-06-05 | — | — | EP | disclosed |
| EP-1184370-A2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| US-6274584-B1 | PEPTIDE DERIVATIVES; BIOAVAILABILITY; ENZYME RESISTANCE; MILK AND WOOL PRODUCTION | NOVO NORDISK A/S (DK) | 2001-08-14 | — | — | US | disclosed |
| US-6127354-A | FOR TREATMENT OF GROWTH DISORDERS OR TO STIMULATE PRODUCTION OF WOOL OR MILK | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5922770-A | NOVEL COMPOUNDS THAT STIMULATE THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 1999-07-13 | — | — | US | disclosed |
| EP-0923539-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998003473-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | AKR1B1 4236/4885HSPA5 929/4885TSHR 4336/4885 |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | AKR1B1 4152/4885HSPA5 901/4885TSHR 4394/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | AKR1B1 4236/4885HSPA5 929/4885TSHR 4336/4885 |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | AKR1B1 4152/4885HSPA5 901/4885TSHR 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.